Outlook Therapeutics has applied to the Centers for Medicare and Medicaid Services (CMS) for a permanent, product-specific HCPCS Level II J-code for Lytenava (bevacizumab-vikg), as the company prepares to launch the wet age-related macular degeneration (AMD) treatment in the United States.

Lytenava is an ophthalmic formulation of bevacizumab. In July 2026, it became the first FDA-approved ophthalmic bevacizumab for wet AMD. Outlook said it remains on track for a US commercial launch before the end of 2026.

A permanent J-code would provide a product-specific billing code for Lytenava when administered in physician practices. CMS reviews HCPCS Level II applications for drugs and biologics quarterly.

Bevacizumab-vikg is a recombinant humanized IgG1 monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A), inhibiting its interaction with VEGFR-1 and VEGFR-2.

Lytenava is also authorized for treatment of wet AMD in the European Union and United Kingdom, where it is known as bevacizumab gamma. RP